04 September 2024
04 September 2024
The $4.2bn all-cash transaction, announced in June 2024, will see the Critical Care product group being renamed as BD Advanced Patient Monitoring.
The US state of California has passed a law banning the use of a toxic chemical produced by certain kinds of plastics from the state's medical devices, catching up with safety legislation that has existed away from the healthcare industry for almost a decade.
The deal between the two companies comes in response to a US Act that calls for the creation of standards for preserving organs on commercial flights.
The EU’s revised MDR 2017/745 was introduced in 2017 and became fully applicable to all medical devices on 27 May 2024.
The Auryon system is intended to treat in-stent restenosis (ISR) lesions and critical limb ischaemia (CLI) in arteries of patients with PAD.
This trial will analyse safety and efficacy signals by determining the ONCObind procedure haemoperfusion filter’s capability to eliminate CTCs in PDAC patients.
The Minima Growth Stent can be implanted in patients as young as a few days old and weighing at least 1.5kg.
Paragard is known for being a non-hormonal contraceptive and provides an efficacy exceeding 99% for up to ten years.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
